936P - Prognostic factors of disease-free survival in vulvar cancer patients

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Vulvar and Vaginal Cancers
Presenter Yuriy Poryvaev
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors Y. Poryvaev, G.A. Nerodo, V. Ivanova, E. Nerodo
  • Department Of Gynecology, Rostov Research Oncological Institute, 344037 - Rostov on Don/RU



The purpose of the study was to analyze disease-free survival in vulvar cancer patients in dependence of different factors.


Disease-free survival in 203 patients with vulvar cancer was determined in dependence on the disease stage, depth of tumor invasion and method of treatment. There were 30 (14,7%) patients with stage I, 49 (24,13%) patients with stage II, 87 (42,85%) with stage III, 37 (18,22%) with stage IV.


Relapses occurred in 18,29% patients with stage I, 20,5% with stage II, 26,68% with stage III, 46,25% with stage IV. Five-year disease-free survival was 46,7% in stage I, 22,4% in stage II, three-year survival was 2,5% in stage III, one-year survival in stage IV was 2,7%. The next significant factor was depth of tumor invasion. Patients with stage I and invasion up to 5 mm - five-year survival 50%, invasion over 5 mm – two-year survival 2,4%. The same proportions were observed in patients with stage III: with invasion up to 5 mm – three-year survival 3,4%, invasion over 5 mm – one-year invasion 45,7%. When detecting disease-free survival in every stage in dependence on primary treatment, positive influence of chemotherapy in complex treatment was confirmed. In stage II patients under combined treatment disease-free five-year survival was 13,8%, with chemotherapy – 35%; in stage III patients under combined treatment disease-free one-year survival was 40%, with chemotherapy – 66,7%, two-year survival under complex treatment – 17,8%, under combined – all patients without relapses died in less than two years.


Thus, disease-free survival of patients depends on the disease stage, depth of tumor invasion and the treatment.


All authors have declared no conflicts of interest.